Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type 1 diabetes

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 11, 2010, Pages 1064-1070

  Toba, Hiroe ^a   Mitani, Takuya ^a   Takahashi, Tamotsu ^a   Imai, Nobuyoshi ^a   Serizawa, Ryoko ^a   Wang, Jiahong ^a   Kobara, Miyuki ^a   Nakata, Tetsuo ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Aldosterone; Angiotensin; Kidney; Pitavastatin

Indexed keywords

ALDOSTERONE; CHOLESTEROL; COLLAGEN; COLLAGEN TYPE 1; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSE; HEMOGLOBIN A1C; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PITAVASTATIN; POTASSIUM ION; SODIUM ION; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY HOMOGENATE; MONOCYTE; NITROGEN CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL;

ALDOSTERONE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; KIDNEY; MALE; PEPTIDYL-DIPEPTIDASE A; QUINOLINES; RATS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE;

EID: 78049314926     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05436.x     Document Type: Article

References (54)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994; 344: 1383-9.
2. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 1995; 333: 1301-7.
3. Landmesser U, Bahlmannn F, Mueller M et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356-63. Epub 005 May 2.
4. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1/month. Circulation 1997; 95: 1126-31.
5. Treasure CB, Klein JL, Weintraub WS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 1995; 332: 481-7.
6. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am. J. Kidney Dis. 2003; 41: 565-70.
7. Kano K, Nishikura K, Yamada Y, Arisaka O. No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria. Clin. Nephrol. 2005; 63: 74-9.
8. Nakamura T, Ushiyama C, Hirokawa K et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol. Dial. Transplant. 2002; 17: 798-802.
9. Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis 2009; 5: 5.
10. Gueler F, Rong S, Park JK et al. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J. Am. Soc. Nephrol. 2002; 13: 2288-98.
11. Li C, Yang CW, Park JH et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am. J. Physiol. Renal Physiol. 2004; 286: F46-57. Epub 2003 Sep 30.
12. Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 2003; 46: 843-51. Epub 2003 May 27.
13. Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 2002; 40: 142-7.
14. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003; 108: 839-43. Epub 2003 Jul 28.
15. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ. Res. 2005; 97: 1232-5.
16. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-8.
17. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33: 232-7.
18. Rocha R, Stier CT Jr, Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-8.
19. Bayorh MA, Ganafa AA, Eatman D, Walton M, Feuerstein GZ. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. Am. J. Hypertens. 2005; 18: 1496-502.
20. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-4.
21. Shinozaki K, Nishio Y, Ayajiki K et al. Pitavastatin restores vascular dysfunction in insulin-resistant state by inhibiting NAD(P)H oxidase activity and uncoupled endothelial nitric oxide synthase-dependent superoxide production. J. Cardiovasc. Pharmacol. 2007; 49: 122-30.
22. Wassmann S, Laufs U, Baumer AT et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-7.
23. Yagi S, Aihara K, Ikeda Y et al. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ. Res. 2008; 102: 68-76. Epub 2007 Oct 25.
24. Doi T, Sakoda T, Akagami T et al. Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2008; 295: H1279-87. Epub 2008 Jul 25.
25. Bilous RW, Mauer SM, Sutherland DE, Steffes MW. Mean glomerular volume and rate of development of diabetic nephropathy. Diabetes 1989; 38: 1142-7.
26. Ziyadeh FN, Goldfarb S. The diabetic renal tubulointerstitium. Curr. Top. Pathol. 1995; 88: 175-201.
27. Ziyadeh FN, Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int. 1991; 39: 464-75.
28. Sassy-Prigent C, Heudes D, Mandet C et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000; 49: 466-75.
29. Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 2000; 58: 684-90.
30. Schneider A, Panzer U, Zahner G et al. Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-beta. Kidney Int. 1999; 56: 135-44.
31. Park JK, Muller DN, Mervaala EM et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. 2000; 58: 1420-30.
32. Kim SI, Han DC, Lee HB. Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J. Am. Soc. Nephrol. 2000; 11: 80-7.
33. Qin J, Zhang Z, Liu J et al. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int. 2003; 64: 565-71.
34. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care. 2005; 28: 2728-32.
35. Ohmura C, Watada H, Hirose T, Tanaka Y, Kawamori R. Acute onset and worsening of diabetes concurrent with administration of statins. Endocr. J. 2005; 52: 369-72.
36. Taira M, Toba H, Murakami M et al. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur. J. Pharmacol. 2008; 589: 264-71. Epub 2008 Jun 10.
37. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001; 345: 870-8.
38. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 1993; 329: 1456-62.
39. Xue C, Siragy HM. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 2005; 46: 584-90. Epub 2005 Jul 25.
40. Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 2000; 35: 1078-84.
41. Dusting GJ. Nitric oxide in cardiovascular disorders. J. Vasc. Res. 1995; 32: 143-61.
42. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991; 43: 109-42.
43. Kashiwagi M, Shinozaki M, Hirakata H et al. Locally activated renin-angiotensin system associated with TGF-beta1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J. Am. Soc. Nephrol. 2000; 11: 616-24.
44. Gonzalez W, Fontaine V, Pueyo ME et al. Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension: modulation of proinflammatory signals. Hypertension 2000; 36: 103-9.
45. Greer JJ, Kakkar AK, Elrod JW, Watson LJ, Jones SP, Lefer DJ Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure. Am. J. Physiol. Heart Circ. Physiol. 2006; 291: H2743-51. Epub 006 Jul 14.
46. Jones SP, Gibson MF, Rimmer DM III, Gibson TM, Sharp BR, Lefer DJ. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J. Am. Coll. Cardiol. 2002; 40: 1172-8.
47. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
48. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 1998; 273: 24266-71.
49. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997; 11: 2295-322.
50. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996; 6: 986-94.
51. Kijima K, Matsubara H, Murasawa S et al. Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. Circ. Res. 1996; 79: 887-97.
52. Komuro I, Yazaki Y. Control of cardiac gene expression by mechanical stress. Annu. Rev. Physiol. 1993; 55: 55-75.
53. Kuwahara K, Saito Y, Nakagawa O et al. The effects of the selective ROCK inhibitor, Y27632, on ET-1-induced hypertrophic response in neonatal rat cardiac myocytes-possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. FEBS Lett. 1999; 452: 314-18.
54. Takemoto M, Node K, Nakagami H et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 2001; 108: 1429-37.